CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to AZN

Olaparib Continuous (28-Day cycle) 300 mg BD.

Phase 2
AstraZeneca PLC (AZN)

Phase 2

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Metastatic Triple Negative Breast Cancer

View Full Landscape
Drug Information

Target Indication

Metastatic Triple Negative Breast Cancer

Clinical Trial

NCT03330847

Last updated: 2/9/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.